The Cost-Effectiveness of Efgartigimod Alfa (Vyvgart) in the Treatment of Myasthenia Gravis: An Insight

By Staff Writer

December 18, 2023

 The Purpose and Pricing of Efgartigimod Alfa

Efgartigimod Alfa, a drug designed to ameliorate symptoms of Generalised Myasthenia Gravis (gMG), has been reimbursed since April 2023 in Japan. The drug is priced at JPY 421,455 for Vyvgart® for intravenous infusion 400 mg as of September 2023. Center for Outcomes Research and Economic Evaluation for Health (C2H) calculate the price using a model for the Efgartigimod Alfa Cost-effectiveness. They then add a 5% usefulness premium and a 10% market premium. 

The Scope of the Efgartigimod Alfa Cost-effectiveness

The cost-effectiveness evaluation of Efgartigimod alfa targets two populations: acetylcholine receptor antibody-positive and antibody-negative patients. The comparators were prednisolone ± immunosuppressive drug ± acetylcholinesterase inhibitor.

Evaluation of Additional Benefits

The manufacturer did not conduct a systematic review in the base case analysis but evaluated the additional benefits of Efgartigimod alfa for patients with gMG as a whole. The academic group decided to evaluate based on scope. They assessed additional benefits for each population using the ADAPT trial. 

Results of the Cost-effectiveness Analysis

The manufacturer conducted a cost-utility analysis using a Markov model, which had states of Efgartigimod alfa or the comparator as first-line treatments, intravenous immunoglobulin or plasma exchange as second-line treatments, eculizumab as third-line treatment (only for population [a]), and the best supportive care.

The Expert Committee of Cost-Effectiveness Evaluation accepted the following:

Reference url

Recent Posts

Medicare drug negotiations
    

Medicare Drug Negotiations Target Ozempic and Ibrance for Price Cuts

💡 *Could Medicare’s latest drug negotiations change the landscape of prescription costs?*
The Centers for Medicare and Medicaid Services has announced its second round of negotiations for crucial medications like Ozempic and Ibrance. This strategic move aims to lower prescription drug prices, potentially benefiting millions of beneficiaries while reshaping health policy under the Biden administration.

Unlock insights into how these negotiations could impact healthcare affordability and access—click to read more!

#SyenzaNews #HealthcarePolicy #CostEffectiveness

healthcare biotechnology Africa
       

Transforming Africa through Healthcare Biotechnology Innovation

🌍 Is healthcare biotechnology the key to Africa’s development?

A recent article highlights how this sector is not only addressing critical health challenges—from infectious diseases to non-communicable conditions—but also driving economic growth and job creation across the continent.

Discover the transformative impact of biotechnology on Africa’s health landscape and its potential to innovate medical solutions tailored for the region.

#SyenzaNews #biotechnology #HealthcareInnovation

Cholera vaccination campaign
       

Cholera Vaccination Campaign Amid Ongoing Outbreak

🌍 How are we tackling the cholera outbreak in South Sudan?

The newly launched cholera vaccination campaign in Rubkona County aims to protect over 300,000 vulnerable individuals facing severe health challenges. Supported by key international organisations like the WHO and UNICEF, this collaborative effort highlights the urgent need for comprehensive healthcare strategies.

Let’s unite in the fight against cholera and support sustainable health initiatives!

#SyenzaNews #globalhealth #healthforall #HealthcareInnovation #MarketAccess

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.